Autolus Therapeutics (AUTL) Revenue & Revenue Breakdown
Autolus Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.70M
Main Segment (Y)
License
Main Geography (Y)
UNITED STATES
Autolus Therapeutics Revenue by Period
Autolus Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.70M | -72.59% |
| 2022-12-31 | $6.19M | 165.84% |
| 2021-12-31 | $2.33M | 862.81% |
| 2020-12-31 | $242.00K | -91.68% |
| 2019-12-31 | $2.91M | 178.19% |
| 2018-09-30 | $1.05M | -38.25% |
| 2017-09-30 | $1.69M | 39.69% |
| 2016-09-30 | $1.21M | - |
Autolus Therapeutics generated $1.70M in revenue during NA 2023, up -72.59% compared to the previous quarter, and up 162.43% compared to the same period a year ago.
Autolus Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $10.09M | 468.51% |
| 2023-12-31 | $1.77M | 337.19% |
| 2023-09-30 | $406.00K | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $1.29M | -66.22% |
| 2022-12-31 | $3.83M | 61.46% |
| 2022-09-30 | $2.37M | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $166.00K | -79.83% |
| 2021-12-31 | $823.00K | 248.73% |
| 2021-09-30 | $236.00K | -84.34% |
| 2021-06-30 | $1.51M | 460.22% |
| 2021-03-31 | $269.00K | -130.81% |
| 2020-12-31 | $-873.00K | -460.74% |
| 2020-09-30 | $242.00K | -17.41% |
| 2020-06-30 | $293.00K | -13.31% |
| 2020-03-31 | $338.00K | 9.39% |
| 2019-12-31 | $309.00K | 4.04% |
| 2019-09-30 | $297.00K | -12.13% |
| 2019-06-30 | $338.00K | -82.79% |
| 2019-03-31 | $1.96M | 563.51% |
| 2018-12-31 | $296.00K | -3.58% |
| 2018-09-30 | $307.00K | -30.70% |
| 2018-06-30 | $443.00K | 3.99% |
| 2018-03-31 | $426.00K | 4.93% |
| 2017-09-30 | $406.00K | - |
| 2017-06-30 | $406.00K | -7.83% |
| 2017-03-31 | $440.50K | - |
| 2016-12-31 | $440.50K | - |
Autolus Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Autolus Therapeutics Revenue Breakdown
Autolus Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Royalty | - | - | - | - |
| License | $1.70M | $3.50M | $242.00K | - |
| Grant | - | $166.00K | $823.00K | $1.47M |
Autolus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 20 | Sep 20 |
|---|---|---|---|
| License | $10.10M | - | $242.00K |
| Grant | - | $1.03M | $438.00K |
Autolus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License (100.00%).
Autolus Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| UNITED STATES | $1.35M | $6.19M | $1.51M |
Autolus Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (100.00%).
Quarterly Revenue by Country
| Country | Mar 24 | Sep 20 |
|---|---|---|
| UNITED STATES | - | - |
| GERMANY | $10.09M | - |
| Grant | - | $438.00K |
| License | - | $242.00K |
Autolus Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: GERMANY (100.00%).
Autolus Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| VECT | VectivBio | $27.34M | $676.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| AUTL | Autolus Therapeutics | $1.70M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CGEM | Cullinan Oncology | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| CELC | Celcuity | - | - |
AUTL Revenue FAQ
What is Autolus Therapeutics’s yearly revenue?
Autolus Therapeutics's yearly revenue for 2023 was $1.7M, representing a decrease of -72.59% compared to 2022. The company's yearly revenue for 2022 was $6.19M, representing an increase of 165.84% compared to 2021. AUTL's yearly revenue for 2021 was $2.33M, representing an increase of 862.81% compared to 2020.
What is Autolus Therapeutics’s quarterly revenue?
Autolus Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $10.09M, a 468.51% increase from the previous quarter (Q4 2023), and a 681.04% increase year-over-year (Q1 2023). AUTL's quarterly revenue for Q4 2023 was $1.78M, a 337.19% increase from the previous quarter (Q3 2023), and a -53.59% decrease year-over-year (Q4 2022).
What is Autolus Therapeutics’s revenue growth rate?
Autolus Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -27.12%, and for the last 5 years (2019-2023) was -41.61%.
What are Autolus Therapeutics’s revenue streams?
Autolus Therapeutics's revenue streams in c 23 are License
What is Autolus Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Autolus Therapeutics was License. This segment made a revenue of $1.7M, representing 100.00% of the company's total revenue.